Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection
Top Cited Papers
- 15 August 2004
- journal article
- lung cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (16) , 3255-3260
- https://doi.org/10.1200/jco.2004.11.109
Abstract
Purpose: A retrospective review of surgically treated lung cancer patients imaged preoperatively by F-18 fluorodeoxyglucose–positron emission tomography ([18F]FDG-PET) to determine if the primary tumor standardized uptake value (SUV) predicts survival. Patients and Methods: Non–small-cell lung cancer or carcinoid pT1–4, N0–2, M0 patients treated by R0 surgical resection alone were imaged with computed tomography scan and PET within 90 days before surgery. Prognostic variables were assessed by log-rank test; survival was assessed by the method of Kaplan and Meier. Results: One hundred consecutive patients (48 men, 52 women) were retrospectively reviewed. Median follow-up for surviving patients was 28 months (range, 16 to 81 months). Median maximal SUV (SUVMAX) was 9. The 2-year survival for patients with SUVMAX more than 9 was 68% and for those with SUVMAX less than 9, it was 96% (P < .01, log-rank test). In a multivariate analysis including pathologic tumor size, involved nodes, histology, and SUVMAX, only tumor size (T) more than 3 cm and SUVMAX more than 9 and their interaction were significant predictors of survival (P = .01, 0.02, and < 0.01, respectively). The 3-year survivals for patients with both T less than 3 cm and SUVMAX less than 9 was 97%; for those with T less than 3 cm and SUVMAX more than 9, it was 94%; for those with T more than 3 cm and SUVMAX less than 9, it was 93%; and for those with T more than 3 cm and SUVMAX more than 9, it was 47% (P < .01). Conclusion: In surgically managed lung cancer patients, SUV is a predictor of overall survival after resection. The addition of SUVMAX to pathologic tumor size identifies a subgroup of patients at highest risk for death as a result of recurrent disease after resection.Keywords
This publication has 14 references indexed in Scilit:
- Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Tumor Dimension and Prognosis in Surgically Treated Lung CancerAmerican Journal of Clinical Oncology, 2003
- Induction chemotherapy before surgery for early-stage lung cancer: A novel approachThe Journal of Thoracic and Cardiovascular Surgery, 2000
- Revisions in the International System for Staging Lung CancerChest, 1997
- Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET)The Journal of Thoracic and Cardiovascular Surgery, 1995
- Tumor doubling time and prognostic assessment of patients with primary lung cancerCancer, 1994
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1994
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994
- Prognostic significance of flow cytometry in lung cancer. A 5-year studyCancer, 1987